AFFILIATIONS
1 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
2 Fudan University Shanghai Cancer Center, Shanghai, China
3 Jiangxi Cancer Hospital, Nanchang, China
4 First Affiliated Hospital of Xi’an Jiaotong University, Xian, China
5 Harbin Medical University Cancer Hospital, Harbin, China
6 Hubei Cancer Hospital, Hubei, China
7 Sichuan Academy of Medical Sciences & Sichuan Provincial People’s Hospital, Chengdu, China
8 The Second Affiliated Hospital of Dalian Medical University, Dalian, China
9 Shanxi Cancer Hospital, Shanxi, China
10 The Affiliated Hospital of Southwest Medical University, Luzhou, China
11 Lymphoma Center, Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China
12 Gansu Provincial Cancer Hospital, Lanzhou, China
13 The Fourth Hospital of Hebei Medical University, Shijiazhuang, China
14 Cancer Hospital of Shandong First Medical University, Jinan, China
15 Zhongnan Hospital of Wuhan University., Wuhan, China
16 Nanjing Drum Tower Hospital, Nanjing, China
17 The First Affiliated Hospital of Soochow University, Suzhou, China
18 Guangxi Medical University Cancer Center, Nanning, China
19 Department of Hematology, the First Affiliated Hospital, Zhejiang University School of Medicine, Hangzhou, China
20 Henan Cancer Hospital, Zhengzhou, China
21 The First Affiliated Hospital of Wannan Medical College, Wuhu, China
22 Weihai Central Hospital, Weihai, China
23 The Second Xiangya Hospital of Central South University, Hunan, China
24 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
25 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
26 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
27 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
28 Department of Medical Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China
29 Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China
30 Chia Tai Tianqing Pharmaceutical Group Co., Ltd., Nanjing, China
ABSTRACT
Background
Diffuse large B-cell lymphoma (DLBCL) is an aggressive malignancy for which frontline immunochemotherapy offers the potential for cure; however, approximately 30%-40% of patients (pts) will develop relapsed/refractory (R/R) disease, with limited options and poor prognosis, particularly in those who have progressed after multiple lines of therapy. GemOx is a standard salvage regimen with a manageable safety profile, providing a rational opportunity for combination with novel targeted agents. TQB2825 is a novel CD20xCD3 bispecific antibody with an anti-CD20 to anti-CD3 structural ratio of 2:1. We present results from a single-arm, multicenter phase II study (NCT06854445) evaluating TQB2825 in combination with GemOx in patients with R/R DLBCL.
Methods
Pts aged ≥18 years with histologically-confirmed DLBCL per WHO classification, measurable disease per Lugano 2014 criteria, and an Eastern Cooperative Oncology Group performance status (ECOG PS) of 0–1 were recruited. Patients were eligible if they had received ≥1 prior line of systemic therapy, including anti-CD20-based, relapsed or were refractory to the last therapy, and were deemed ineligible for autologous stem cell transplantation. Pts were administered TQB2825 in combination with 6 cycles of GemOx, followed by maintenance of TQB2825 monotherapy until disease progression, intolerable toxicity, or withdrawal. Six pts were enrolled in TQB2825 prior to chemotherapy (Schedule 1) and TQB2825 after chemotherapy (Schedule 2), respectively. The primary endpoint was CR rate.
Results
As of data cutoff date on June 12, 2026, the median follow-up of 8.74 months (95% confidence interval (CI): 7.06–9.86). No significant difference in toxicity was observed between the two schedules. Accordingly, Schedule 1 was selected for dose expansion, and a total of 40 pts enrolled across the entire study. The expansion dose was selected as TQB2825 80 mg with Schedule 1, administered as a step-up dosing (0.3 mg → 3 mg → 30 mg in Cycle 1, then 80 mg weekly in Cycles 2–3, and 80 mg Q3W from Cycle 4 onward).
46 pts (80mg with schedule1: n=40, 80mg with schedule 2: n=6) were enrolled in the 80 mg cohort. Pts had a median age of 61 years (range, 37–78), with 19 (41.3%) aged ≥65 years; 36 (78.3%) had ECOG PS 1, and 34 (73.9%) had advanced-stage (III–IV) disease. 27 pts (58.7%) had received 1 prior line of therapy and 19 (41.3%) had ≥2 prior lines; 14 (30.4%) were refractory to last therapy, and 3 (6.5%) had prior CAR-T therapy.
The ORR was 77.3% (34/44; 95% CI: 61.0–85.3), with a CR rate of 52.3% (23/44; 95% CI: 33.6–61.2). The median time to response was 1.9 months (range: 1.8–7.0). Among 34 responders, the median duration of response (DOR) was 2.14 months (95% CI: 1.68–NR); the 6-month and 12-month DOR rates were 65.3% and 57.1%, respectively. The median progression-free survival (PFS) was 9.9 months (95% CI: 4.6–NC), PFS data were not yet mature.
All 46 pts were evaluable for safety. Grade ≥3 TQB2825-related treatment-emergent adverse events (TEAEs) occurred in 33 pts (71.7%). The most frequent grade ≥3 TQB2825-related TEAEs were thrombocytopenia (44.8%), neutropenia (27.6%), and leukopenia (15.2%). Cytokine release syndrome (CRS) occurred in 15 pts (32.6%; grade 1: 23.9%, grade 2: 8.7%), with no grade ≥3 CRS reported. Immune effector cell-associated neurotoxicity syndrome did not occur. No treatment-related death occurred.
Conclusion
TQB2825 in combination with GemOx showed promising antitumor activity in pts with R/R DLBCL. The safety profile was manageable, with CRS being predominantly low grades, no ICANS. TQB2825 combined with GemOx might be a promising treatment regimen for pts with R/R DLBCL, which warrants further evaluation in randomized studies.